SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-013952
Filing Date
2023-04-24
Accepted
2023-04-24 09:00:16
Documents
9
Period of Report
2023-06-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A alxo_def_14a_2023_proxy.htm DEF 14A 1368024
2 GRAPHIC img60516838_0.jpg GRAPHIC 7391
3 GRAPHIC img60516838_1.jpg GRAPHIC 4688
4 GRAPHIC img60516838_2.jpg GRAPHIC 4028
5 GRAPHIC img60516838_3.jpg GRAPHIC 4028
6 GRAPHIC img60516838_4.jpg GRAPHIC 55997
7 GRAPHIC img60516838_5.jpg GRAPHIC 61970
8 GRAPHIC img60516838_6.jpg GRAPHIC 121949
9 GRAPHIC img60516838_7.jpg GRAPHIC 127537
  Complete submission text file 0000950170-23-013952.txt   1903783
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

IRS No.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39386 | Film No.: 23838038
SIC: 2834 Pharmaceutical Preparations